Laboratory of Molecular Reproduction and Fertility Preservation, Obstetrics and Gynecology, New York Medical College, Valhalla, New York, USA.
Fertil Steril. 2012 Dec;98(6):1363-9. doi: 10.1016/j.fertnstert.2012.09.022. Epub 2012 Oct 9.
Breast cancer is the most common malignancy diagnosed in women in the United States. Many breast cancer survivors are concerned that cancer treatment will compromise their reproductive potential. Despite this concern, most women receive limited information addressing preservation of fertility before initiating adjuvant chemotherapy. Historically, the supraphysiologic levels of estrogens associated with ovarian stimulation have precluded the use of assisted reproductive technologies in the presence of breast cancer. In an effort to mitigate the potential effects of elevated estrogen levels during ovulation induction, we developed a novel ovarian stimulation protocol for women with breast cancer, with the use of aromatase inhibitors. Our studies suggest that in the short term, aromatase inhibitors plus gonadotropins are safe and effective agents for ovarian stimulation in fertility preservation cycles. In this review, we outline the data supporting the use of aromatase inhibitors for ovarian hyperstimulation in women with breast cancer before initiating adjuvant chemotherapy.
乳腺癌是美国女性最常见的恶性肿瘤。许多乳腺癌幸存者担心癌症治疗会损害她们的生殖潜能。尽管存在这种担忧，但大多数女性在开始辅助化疗之前，获得的有关生育力保存的信息非常有限。历史上，与卵巢刺激相关的超生理水平雌激素排除了在存在乳腺癌的情况下使用辅助生殖技术。为了减轻排卵诱导期间雌激素水平升高的潜在影响，我们为患有乳腺癌的女性开发了一种新的卵巢刺激方案，使用芳香酶抑制剂。我们的研究表明，在短期内，芳香酶抑制剂加促性腺激素是生育力保存周期中卵巢刺激的安全有效的药物。在这篇综述中，我们概述了支持在开始辅助化疗前使用芳香酶抑制剂对患有乳腺癌的女性进行卵巢超刺激的数据。
